Immunomedics: Sacituzumab Govitecan Awarded FDA Fast Track Designation

(RTTNews) - Immunomedics, Inc. (IMMU) announced it has received notice from the U.S. FDA designating as a Fast Track development program the investigation of sacituzumab govitecan, the company's lead antibody-drug conjugate, for the treatment of patients with triple-negative breast cancer who have failed prior therapies for metastatic disease.

Previously, FDA granted Fast Track status to sacituzumab govitecan for the therapy of patients with small-cell lung cancer. Sacituzumab govitecan has also been designated an orphan drug by FDA for the treatment of patients with small-cell lung or pancreatic cancers.